SIBU: Sarawak Premier Tan Sri Abang Johari Openg has announced ambitious plans to construct a London Bridge-inspired crossing ...

The FDA has granted an accelerated approval for atrasentan to reduce elevated protein in the urine in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression ...

The ORIGIN Phase 2b trial previously demonstrated that atacicept significantly reduced proteinuria and stabilized kidney function over 96 weeks, suggesting it could be a leading therapy for IgAN.

The ORIGIN 3 trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of atacicept—a recombinant fusion protein targeting B-cell modulators—for ...

It has not been established whether Vanrafia slows kidney function decline in patients with IgAN. The company noted that the continued approval of Vanrafia may be contingent upon the verification ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

For the freshest news, join The Borneo Post's Telegram Channel and The Borneo Post on Newswav.

The U.S. FDA’s accelerated approval of Vanrafia (atrasentan) from Novartis AG for primary immunoglobulin A nephropathy (IgAN) is the company’s second approval for the indication in the past year and a ...